Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 25913
Gene Symbol: POT1
POT1
0.300 Biomarker group CTD_human POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. 23502782 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker group BEFREE Median age was 46 (range: 16-76) years, acute myeloid leukemia was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. 31004014 2020
Entrez Id: 3014
Gene Symbol: H2AX
H2AX
0.100 Biomarker group BEFREE Furthermore, the sensitivity of Ligase4<sup>-/-</sup> cells was associated with enhanced DNA damage when comparing the accumulation of γ-H2AX foci and number of chromosomal aberrations (CAs) with WT cells. 30070703 2019
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.100 Biomarker group BEFREE MYCN status, ploidy and chromosomal aberrations), and UCNB complications (i.e. bleeding, pain, or anesthesiologic complications). 30700386 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation group BEFREE However, both cell systems have suboptimal features, with HaCaT cells exhibiting a large number of chromosomal aberrations and mutated p53 tumor suppressor, whereas primary keratinocytes are short-lived, heterogeneous and not susceptible to genetic modifications due to their restricted life-span. 31247885 2019
Entrez Id: 28471
Gene Symbol: IGHV1-12
IGHV1-12
0.100 Biomarker group BEFREE The tumor is thought to be histogenetically less associated with HPV infection, and its teratomatous components with an absence of cytogenetic abnormalities (including isochromosome 12p (i(12p)) suggest a analogous histogenesis compared to pure mature or immature teratoma. 31684979 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.100 GeneticVariation group BEFREE Using a comprehensive genomic profiling, we were able to identify recurrent chromosomal aberrations associated with MS including a rare KMT2A-ELL fusion, losses of chromosomes 1p, 9, 10, 15, 18, and gain of chromosome 1q and mutations in FLT3 and PTPN11, and achived the final diagnosis of a de novo MS. 30922345 2019
Entrez Id: 3342
Gene Symbol: HTC2
HTC2
0.100 Biomarker group BEFREE Therefore, a Gaussian pdf is not adequate to approximate the noise in array CGH data and hence introduces wrong detections of chromosomal aberrations and leads misunderstanding on disease pathogenesis. 28692986 2019
Entrez Id: 102723407
Gene Symbol: LOC102723407
LOC102723407
0.100 GeneticVariation group BEFREE The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. 31054420 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation group BEFREE TP53 mutated patients had even fewer co-mutated genes but were enriched for the del(5q) chromosomal abnormality (p < 0.005), monosomal karyotype (p < 0.001), and high complexity, defined as more than 4 cytogenetic abnormalities (p < 0.001). 30635634 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation group BEFREE Mutation frequencies of SF3B1 (9·7%), NOTCH1 (8·6%), BIRC3 (1·1%), ATM (16·9%) or TP53 (8·1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18·6%), del(17p) (10·4%), del(13q) (43·7%) and IGH translocation (10·1%) were comparable to those reported from Western countries, except del(11q) (6·9%) which was lower in our patients. 31230372 2019
Entrez Id: 3342
Gene Symbol: HTC2
HTC2
0.100 GeneticVariation group BEFREE Patients with atypical values of HCG and/or PAPP-A are at higher risk of chromosomal abnormality and vascular complications of pregnancy. 31779618 2019
Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
0.100 Biomarker group BEFREE Cases with mutated and unmutated IGHV status showed increased CA and MN frequencies compared to controls (P ≤ 0.0007), but no differences between both groups were found. 31037299 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation group BEFREE Mutation frequencies of SF3B1 (9·7%), NOTCH1 (8·6%), BIRC3 (1·1%), ATM (16·9%) or TP53 (8·1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18·6%), del(17p) (10·4%), del(13q) (43·7%) and IGH translocation (10·1%) were comparable to those reported from Western countries, except del(11q) (6·9%) which was lower in our patients. 31230372 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation group BEFREE Using the ALWP/EBMT registry we conducted a retrospective analysis to determine the clinical outcomes of AML patients undergoing allo-HSCT with respect to specific recurring cytogenetic abnormalities complemented with FLT3-ITD status. 30846862 2019
Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
0.100 GeneticVariation group BEFREE The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. 31054420 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker group BEFREE Cases with mutated and unmutated IGHV status showed increased CA and MN frequencies compared to controls (P ≤ 0.0007), but no differences between both groups were found. 31037299 2019
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.100 Biomarker group BEFREE Detailed examination of placenta including MYCN amplification and segmental chromosomal aberrations should be performed in all suspected cases, as it is noninvasive and readily available. 31094905 2019
Entrez Id: 472
Gene Symbol: ATM
ATM
0.100 GeneticVariation group BEFREE Mutation frequencies of SF3B1 (9·7%), NOTCH1 (8·6%), BIRC3 (1·1%), ATM (16·9%) or TP53 (8·1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18·6%), del(17p) (10·4%), del(13q) (43·7%) and IGH translocation (10·1%) were comparable to those reported from Western countries, except del(11q) (6·9%) which was lower in our patients. 31230372 2019
Entrez Id: 3342
Gene Symbol: HTC2
HTC2
0.100 Biomarker group BEFREE SNP array, array CGH and FISH were useful for the complete characterization of the chromosomal aberrations, for the detection of microdeletions in patients with normal karyotype but with strong clinical suspicious of chromosomal alteration, and for a better establishment of genotype-phenotype correlation. 31730496 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker group BEFREE In contrast, tolerance to structural chromosome aberrations was almost entirely restricted to TP53-knockout clones, all of which were able to continue proliferation in the presence of damaged DNA. 31444400 2019
Entrez Id: 102724971
Gene Symbol: LOC102724971
LOC102724971
0.100 GeneticVariation group BEFREE The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. 31054420 2019
Entrez Id: 102724971
Gene Symbol: LOC102724971
LOC102724971
0.100 Biomarker group BEFREE Cases with mutated and unmutated IGHV status showed increased CA and MN frequencies compared to controls (P ≤ 0.0007), but no differences between both groups were found. 31037299 2019
Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
0.100 Biomarker group BEFREE Cases with mutated and unmutated IGHV status showed increased CA and MN frequencies compared to controls (P ≤ 0.0007), but no differences between both groups were found. 31037299 2019
Entrez Id: 595
Gene Symbol: CCND1
CCND1
0.100 GeneticVariation group BEFREE The cytogenetic abnormality t(11;14) (q13; q32) leading to cyclin D1 overexpression is the sentinel genetic event and provides an exceptional marker for diagnosis. 31776787 2019